In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Paulina Podszywalow-BartnickaNencki Institute of Experimental Biology Polish Academy of Sciences, Warsaw, Poland.ORCID 0000-0002-4965-828X Remigiusz SerwaInternational Institute of Molecular Mechanisms and Machines Polish Academy of Sciences, Warsaw, Poland.ORCID 0000-0002-4684-3754 Joanna IdaszekFaculty of Material Science and Engineering, Warsaw University of Technology, Warsaw, Poland.ORCID 0000-0001-7106-0105 Ewa WalejewskaFaculty of Material Science and Engineering, Warsaw University of Technology, Warsaw, Poland.ORCID 0000-0003-2803-4870 Agnieszka KepczynskaNencki Institute of Experimental Biology Polish Academy of Sciences, Warsaw, Poland.
Anna Mietelska-PorowskaNencki Institute of Experimental Biology Polish Academy of Sciences, Warsaw, Poland.ORCID 0000-0002-3192-8739 Paulina Pilanc-KudlekNencki Institute of Experimental Biology Polish Academy of Sciences, Warsaw, Poland.ORCID 0000-0003-3354-439X Magdalena WolczykNencki Institute of Experimental Biology Polish Academy of Sciences, Warsaw, Poland.ORCID 0000-0001-7115-9308 Leonard SchärfenDepartment of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, USA.ORCID 0000-0003-0234-7609 Bac Viet LeFels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.ORCID 0000-0001-5077-8994 Wojciech SwieszkowskiFaculty of Material Science and Engineering, Warsaw University of Technology, Warsaw, Poland.ORCID 0000-0003-4216-9974 Katarzyna PiwockaNencki Institute of Experimental Biology Polish Academy of Sciences, Warsaw, Poland.ORCID 0000-0001-6676-5282 Tomasz SkorskiFels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.ORCID 0000-0002-3809-4538 Karla M NeugebauerDepartment of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, USA.ORCID 0000-0002-3835-6761 Funding
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Dietmar J Kappes · 1985 to 2026
$138.8MCross-regulation between transcription and pre-mRNA splicingR01GM112766 · NIGMS · YALE UNIVERSITY · PI Karla M Neugebauer · 2015 to 2026
$5.3MBiogenesis and function of a novel class of stress-induced long non-coding RNAsR01GM140735 · NIGMS · YALE UNIVERSITY · PI NEUGEBAUER, KARLA M, STEITZ, JOAN A. · 2021 to 2024
$1.7MHigh Performance Computing Instrumentation for the Yale Center for Genome AnalysisS10OD030363 · OD · YALE UNIVERSITY · PI MANE, SHRIKANT M · 2022 to 2022
$1.2MNCI NIH HHS P30 CA006927NIGMS NIH HHS R01 GM112766NIGMS NIH HHS R01 GM140735NIH HHS S10 OD030363
6 · The paper itselfAbstract
Chronic myeloid leukemia (CML) is treated with Abl1 tyrosine kinase inhibitors (TKIs). Quiescent cancer cells residing in the bone marrow (BM) can survive the treatment and cause CML relapse. We previously found that a subset of alternative splicing (AS) changes detected in CML cells surviving months of therapy are initiated within hours of treatment onset. Here, we investigated how AS in CML cells is modulated by the human BM microenvironment. By incorporating humanized BM niche models
Indexed as
bone marrowhypoxialeukemiaRNA binding proteinstherapy resistancetyrosine kinase inhibitors
Identifiers
PMID42523372
PMCPMC13404965
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390